These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33007314)

  • 1. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
    Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
    Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
    Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
    Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
    Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
    Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
    Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT
    Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
    Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
    Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.
    Carcamo B; Bista R; Wilson H; Reddy P; Pacheco J
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e718-e722. PubMed ID: 34157012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
    Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
    Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
    Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
    Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.